N-acetyltransferase 1*10 genotype in bladder cancer patients

References

• Bell, D. A., Badawi, A. F., Lang, N. P., Ilett, K. F., Kadlubar, F. F., and Hirvonen, A. 1995. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res. 55: 5226–5229.
   PubMed Web of Science ®Google Scholar
• Butcher, N. J., Ilett, K. F., and Minchin, R. F. 2000. Inactivation of human arylamine N-acetyltransferase 1 by the hydroxylamine of p-aminobenzoic acid. Biochem. Pharmacol. 60: 1829–1836.
   PubMed Web of Science ®Google Scholar
• Butcher, N. J. and Minchin, R. F. 2012. Arylamine N-acetyltransferase 1: A novel drug target in cancer development. Pharmacol. Rev. 64: 147–165.
   PubMed Web of Science ®Google Scholar
• Cascorbi, I., Roots, I., and Brockmöller, J. 2001. Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10. Cancer Res. 61: 5051–5056.
   PubMed Web of Science ®Google Scholar
• Covolo, L., Placidi, D., Gelatti, U., Carta, A., Scotto Di Carlo, A., Lodetti, P., Piccichè, A., Orizio, G., Campagna, M., Arici, C., and Porru, S. 2008. Bladder cancer, GSTs, NAT1, NAT2, SULT1A1, XRCC1, XRCC3, XPD genetic polymorphisms and coffee consumption: A case–control study. Eur. J. Epidemiol. 23: 355–362.
   PubMed Web of Science ®Google Scholar
• Cribb, A. E., Grant, D. M., Miller, M. A., and Spielberg, S. P. 1991. Expression of monomorphic arylamine N-acetyltransferase (NAT1) in human leukocytes. J. Pharmacol. Exp. Ther. 259: 1241–1246.
   PubMed Web of Science ®Google Scholar
• Dierolf, D., Scheitza, S., Bonifas, J., and Blömeke, B. 2012. Cyanamide-mediated inhibition of N-acetyltransferase 1. Toxicology 302: 1–10.
   PubMed Web of Science ®Google Scholar
• Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers, C., and Parkin, D. M. 2008. Cancer incidence and mortality worldwide: IARC CancerBase No. 10. GLOBOCAN v2.0. http://globocan.iarc.fr (accessed November 25, 2015)
   Google Scholar
• Freedman, N. D., Silverman, D. T., Hollenbeck, A. R., Schatzkin, A., and Abnet, C. C. 2011. Association between smoking and risk of bladder cancer among men and women. J. Am. Med. Assoc. 306: 737–745.
   PubMed Web of Science ®Google Scholar
• García-Closas, M., Malats, N., Silverman, D., Dosemeci, M., Kogevinas, M., Hein, D. W., Tardón, A., Serra, C., Carrato, A., García-Closas, R., Lloreta, J., Castaño-Vinyals, G., Yeager, M., Welch, R., Chanock, S., Chatterjee, N., Wacholder, S., Samanic, C., Torà, M., Fernández, F., Real, F. X., and Rothman, N. 2005. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 366: 649–659.
   PubMed Web of Science ®Google Scholar
• Golka, K., Bandel, T., Schlaefke, S., Reich, S. E., Reckwitz, T., Urfer, W., Bremicker, K. D., Neugebauer, W., Soekeland, J., and Bolt, H. M. 1998. Urothelial cancer of the bladder in an area of former coal, iron, and steel industries in Germany: A case-control study. Int. J. Occup. Environ. Health 4: 79–84.
   PubMedGoogle Scholar
• Golka, K., Hermes, M., Selinski, S., Blaszkewicz, M., Bolt, H. M., Roth, G., Dietrich, H., Prager, H. M., Ickstadt, K., and Hengstler, J. G. 2009. Susceptibility to urinary bladder cancer: relevance of rs9642880[T], GSTM1 0/0 and occupational exposure. Pharmacogenet. Genomics 19: 903–906.
   PubMed Web of Science ®Google Scholar
• Golka, K., Prior, V., Blaszkewicz, M., and Bolt, H. M. 2002. The enhanced bladder cancer susceptibility of NAT2 slow acetylators towards aromatic amines: a review considering ethnic differences. Toxicol. Lett. 128: 229–241.
   PubMed Web of Science ®Google Scholar
• Golka, K., Wiese, A., Assennato, G., and Bolt, H. M. 2004. Occupational exposure and urological cancer. World J. Urol. 21: 382–391.
   PubMed Web of Science ®Google Scholar
• Grant, D. M., Blum, M., Beer, M., and Meyer, U. A. 1991. Monomorphic and polymorphic human arylamine N-acetyltransferases: A comparison of liver isozymes and expressed products of two cloned genes. Mol. Pharmacol. 39: 184–191.
   PubMed Web of Science ®Google Scholar
• Gu, J., Liang, D., Wang, Y., Lu, C., and Wu, X. 2005. Effects of N-acetyltransferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians. Mutat. Res. 581: 97–104.
   PubMed Web of Science ®Google Scholar
• Hsieh, F. I., Pu, Y. S., Chern, H. D., Hsu, L. I., Chiou, H. Y., and Chen, C. J. 1999. Genetic polymorphisms of N-acetyltransferase 1 and 2 and risk of cigarette smoking-related bladder cancer. Br. J. Cancer 81: 537–541.
   PubMed Web of Science ®Google Scholar
• Hung, R. J., Boffetta, P., Brennan, P., Malaveille, C., Hautefeuille, A., Donato, F., Gelatti, U., Spaliviero, M., Placidi, D., Carta, A., Scotto Di Carlo, A., and Porru, S. 2004. GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high risk population. Int. J. Cancer 110: 598–604.
   PubMed Web of Science ®Google Scholar
• Jaskula-Sztul, R., Sokolowski, W., Gajecka, M., and Szyfter, K. 2001. Association of arylamine N-acetyltransferase (NAT1 and NAT2) genotypes with urinary bladder cancer risk. J. Appl. Genet. 42: 223–231.
   PubMedGoogle Scholar
• Krech, E., Selinski, S., Blaszkewicz, M., Bürger, H., Kadhum, T., Hengstler, J. G., Truss, M. C., and Golka, K. 2017. Urinary bladder cancer risk factors in an area of former coal, iron and steel industries in Germany. J. Toxicol. Environ. Health A DOI 10.1080/10937404.2017.1304719
   Google Scholar
• McGrath, M., Michaud, D., and De Vivo, I. 2006. Polymorphisms in GSTT1, GSTM1, NAT1 and NAT2 genes and bladder cancer risk in men and women. BMC Cancer 6: 239.
   PubMed Web of Science ®Google Scholar
• Millner, L. M., Doll, M. A., Stepp, M. W., States, J. C., and Hein, D. W. 2012. Functional analysis of arylamine N-acetyltransferase 1 (NAT1) NAT1*10 haplotypes in a complete NATb mRNA construct. Carcinogenesis 33: 348–355. Erratum in Carcinogenesis 33: 1431.
   Google Scholar
• Okkels, H., Sigsgaard, T., Wolf, H., and Autrup, H. 1997. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: The influence of smoking. Cancer Epidemiol. Biomarkers Prev. 6: 225–231.
   PubMed Web of Science ®Google Scholar
• Ovsiannikov, D., Selinski, S., Lehmann, M. L., Blaszkewicz, M., Moormann, O., Haenel, M. W., Hengstler, J. G., and Golka, K. 2012. Polymorphic enzymes, urinary bladder cancer risk, and structural change in the local industry. J. Toxicol. Environ. Health A 75: 557–565.
   PubMed Web of Science ®Google Scholar
• Ragunathan, N., Dairou, J., Pluvinage, B., Martins, M., Petit, E., Janel, N., Dupret, J. M., and Rodrigues-Lima, F. 2008. Identification of the xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 as a new target of cisplatin in breast cancer cells: Molecular and cellular mechanisms of inhibition. Mol. Pharmacol. 73: 1761–1768.
   PubMed Web of Science ®Google Scholar
• Ragunathan, N., Dairou, J., Sanfins, E., Busi, F., Noll, C., Janel, N., Dupret, J. M., and Rodrigues-Lima, F. 2010. Cadmium alters the biotransformation of carcinogenic aromatic amines by arylamine N-acetyltransferase xenobiotic-metabolizing enzymes: Molecular, cellular, and in vivo studies. Environ. Health Persp. 118: 1685–1691.
   PubMed Web of Science ®Google Scholar
• RKI Robert Koch Institute and the Association of Population-based Cancer Registries in Germany. Berlin. 2014. Cancer in Germany 2009/2010. 9th Edition. http://www.rki.de/Krebs/EN/Content/Publications/Cancer_in_Germany/cancer_chapters_2009_2010/cancer_germany_2009_2010.pdf?__blob=publicationFile ( accessed May 23, 2016)
   Google Scholar
• Rodrigues-Lima, F., Dairou, J., Busi, F., and Dupret, J. M. 2010. Human arylamine N-acetyltransferase 1: A drug-metabolizing enzyme and a drug target? Curr. Drug Targets 11: 759–766.
   PubMed Web of Science ®Google Scholar
• Roemer, H. C., Weistenhofer, W., Lohlein, D., Geller, F., Blomeke, B., and Golka, K. 2008. N-acetyltransferase 1 in colon and rectal cancer cases from an industrialized area. J. Toxicol. Environ. Health A 71: 902–905.
   PubMed Web of Science ®Google Scholar
• SAS/STAT® software, version 9.4. Copyright © 2002–2008, SAS Institute Inc. Cary, NC, USA.
   Google Scholar
• Selinski, S., Blaszkewicz, M., Ickstadt, K., Hengstler, J. G., and Golka, K. 2013. Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk. Arch. Toxicol. 87: 2129–2139.
   PubMed Web of Science ®Google Scholar
• Statistisches Bundesamt (Hrsg). 1992. Klassifizierung der Berufe. Systematisches und alphabetisches Verzeichnis der Berufsbenennungen. Stuttgart: Metzler-Poeschel Verlag.
   Google Scholar
• Sy, S. K., De Kock, L., Diacon, A. H., Werely, C. J., Xia, H., Rosenkranz, B., Van Der Merwe, L., and Donald, P. R. 2015. N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis. Antimicrob. Agents Chemother. 59: 4129–4138.
   PubMed Web of Science ®Google Scholar
• Taylor, J. A., Umbach, D. M., Stephens, E., Castranio, T., Paulson, D., Robertson, C., Mohler, J. L., and Bell, D. A. 1998. The role of N-acetylation polymorphisms in smoking-associated bladder cancer: Evidence of a gene–gene–exposure three way interaction. Cancer Res. 58: 3603–3610.
   PubMed Web of Science ®Google Scholar
• The Arylamine N-acetyltransferase Gene Nomenclature Committee. 2016 database of arylamine N-acetyltransferases (NATs) http://nat.mbg.duth.gr/(accessed May 06, 2016).
   Google Scholar
• Walker, K., Ginsberg, G., Hattis, D., Johns, D. O., Guyton, K. Z., and Sonawane, B. 2009. Genetic polymorphism in N-acetyltransferase (NAT): Population distribution of NAT1 and NAT2 activity. J. Toxicol. Environ. Health B 12: 440–472.
   PubMed Web of Science ®Google Scholar
• Wang, D., Para, M. F., Koletar, S. L., and Sadee, W. 2011. Human N-acetyltransferase 1 *10 and *11 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity. Pharmacogenet. Genom. 21: 652–664.
   PubMed Web of Science ®Google Scholar
• Windmill, K. F., Gaedigk, A., Hall, P. M., Samaratunga, H., Grant, D. M., and McManus, M. E. 2000. Localization of N-acetyltransferases NAT1 and NAT2 in human tissues. Toxicol. Sci. 54: 19–29.
   PubMed Web of Science ®Google Scholar
• Wu, K., Wang, X., Xie, Z., Liu, Z., and Lu, Y. 2013. N-Acetyltransferase 1 polymorphism and bladder cancer susceptibility: A meta-analysis of epidemiological studies. J. Int. Med. Res. 41: 31–37.
   PubMed Web of Science ®Google Scholar